A phase I/II study of nicotinamide riboside (NR) in patients with Cockayne Syndrome

Trial Profile

A phase I/II study of nicotinamide riboside (NR) in patients with Cockayne Syndrome

Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Nicotinamide riboside (Primary)
  • Indications Cockayne syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Nov 2016 New trial record
    • 11 Nov 2016 According to a Chroma Technology Corporation media release, the company anticipates to file an investigational new drug application for the initiation of this trial in the first quarter of 2017. The FDA has indicated it will consider a Fast Track designation for nicotinamide riboside at the time of the IND submission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top